Klaviyo insider plans sale of 98,782 Series A shares

Klaviyo, Inc. (KVYO) received a Form 144 notice relating to planned sales of its Series A shares for the account of Edward W. Hallen.

Rhea-AI Filing Summary

Klaviyo, Inc. (KVYO) received a Form 144 notice relating to planned sales of its Series A shares for the account of Edward W. Hallen. The notice lists 98,782 shares to be sold, including 59,615 shares from Hodgkins LLC and 39,167 shares from Hodgkins Trust, with Fidelity Brokerage Services LLC acting as broker.

Key Figures

Shares to be sold: 98,782 shares Shares from Hodgkins LLC: 59,615 shares Shares from Hodgkins Trust: 39,167 shares +2 more

5 metrics

Shares to be sold 98,782 shares Series A shares covered by the Form 144 notice

Shares from Hodgkins LLC 59,615 shares Portion of today’s sale from Hodgkins LLC

Shares from Hodgkins Trust 39,167 shares Portion of today’s sale from Hodgkins Trust

Date of Notice 08/31/2026 Date indicated for the Form 144 notice

Issuer phone number 800-338-1744 Contact phone number for Klaviyo, Inc.

Key Terms

Rule 144, Founders Shares, attorney-in-fact, Compensation

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Founders Shares financial

"Series A | 09/25/2012 | Founders Shares | Issuer"

Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

attorney-in-fact regulatory

"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Compensation financial

"98782 | 09/25/2012 | Compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 144 filing mean for KVYO (Klaviyo, Inc.)?

The filing gives notice that 98,782 Series A shares of Klaviyo, Inc. may be sold for the account of Edward W. Hallen, using Fidelity Brokerage Services LLC as broker. It is a disclosure of a potential sale under Rule 144, not a company-issued offering.

How many KVYO shares are involved in Edward W. Hallen’s Form 144?

The notice covers 98,782 Series A shares of Klaviyo, Inc. This total includes 59,615 shares from Hodgkins LLC and 39,167 shares from Hodgkins Trust, both accounts in which Edward W. Hallen is a stakeholder.

Which entities are selling KVYO shares in this Form 144?

Shares are to be sold from Hodgkins LLC and Hodgkins Trust. The remarks state that 59,615 shares are from Hodgkins LLC and 39,167 shares are from Hodgkins Trust, with Edward W. Hallen as an authorized individual or account stakeholder.

Who is the broker for the KVYO shares in this Form 144?

The broker listed is Fidelity Brokerage Services LLC, located in Smithfield, Rhode Island. Fidelity Brokerage Services LLC is named as the firm through which the Series A shares of Klaviyo, Inc. are to be sold.

When was the Form 144 notice for KVYO filed?

The Form 144 notice is dated 08/31/2026. Another date, 06/01/2026, also appears in the notice, but 08/31/2026 is specifically identified as the Date of Notice.

What type of KVYO securities are covered by this Form 144?

The securities described are Series A shares of Klaviyo, Inc. The notice identifies the security as Series A and classifies the original issuance as “Founders Shares,” with the nature of acquisition described as “Compensation.”

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 04:33 PM EDT Accepted by SEC EDGAR 08/31/2026 - 04:32 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001991125
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Klaviyo, Inc.
SEC File Number	001-41806
Address of Issuer	125 SUMMER STREET, FLOOR 6 BOSTON MASSACHUSETTS 02110
Phone	800-338-1744
Name of Person for Whose Account the Securities are To Be Sold	Hallen Ed
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Series A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	98782	2022971.34	126937933	08/31/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Series A	09/25/2012	Founders Shares	Issuer			98782	09/25/2012	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Today's sale includes 59,615 shares sold from Hodgkins Llc, of which Edward W Hallen is an authorized individual and account stakeholder; and 39,167 shares sold from Hodgkins Trust, of which Edward W. Hallen is an account stakeholder.
Date of Notice	08/31/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/01/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Edward W Hallen
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)